As it transitions into a clinical-stage company, genetic therapy startup Ensoma is leaving behind half of its employees. CEO Jim Burns confirmed to Endpoints News that only 37 workers will remain with the company.
All entries for: Ensoma
September 22, 2025
Ensoma
Investment
Boston, MA
51-200 employees
Ensoma raised $53 million to develop in vivo genomic medicines that deliver gene modification technologies directly to blood and immune cells, offering potentially curative treatments in a single injection for rare diseases.
Disease Area: Rare Diseases